Mergers and Acquisitions

BMS investors voice discontent over $74bn Celgene deal

28-Feb-2019 By Ben Hargreaves

BMS has been struck a blow in its plans to acquire Celgene, after its largest investor questioned the risk of the deal.

Merck in $300m Immune Design boost for Keytruda

21-Feb-2019 By Ben Hargreaves

Announced today, the deal sees Merck pay $5.85 per share to acquire Immune Design and its portfolio of late-stage immunotherapies.

Lilly bets $8bn on genomic approach to cancer

07-Jan-2019 By Ben Hargreaves

Eli Lilly will acquire Loxo for $8bn to gain access to treatments that target cancers dependent on single gene abnormalities.

BMS begins year with $74bn Celgene acquisition

03-Jan-2019 By Ben Hargreaves

BMS announced that it will merge with Celgene, bolstering its oncology and immunology/inflammation franchises.

GSK and Pfizer JV creates ‘global leader in OTC products’

19-Dec-2018 By Flora Southey

Pfizer and GSK will combine their consumer healthcare companies in a joint venture – creating an OTC portfolio with 7.3% global market share.

Roquette buys majority stake in India-based excipient manufacturer

17-Dec-2018 By Maggie Lynch

Roquette has purchased a majority stake in excipient manufacturer Crest Cellose, in an aim to increase its footprint in India’s generic pharmaceutical market.

Boehringer reshuffle cuts 327 jobs in France

12-Dec-2018 By Flora Southey

Boehringer says it will reduce its workforce in France, including 182 positions in human health, to streamline operations in ‘deteriorating markets’.

Akorn CEO resigns after Fresenius merger collapses

10-Dec-2018 By Ben Hargreaves

The Supreme Court ruled that Fresenius was within its rights to terminate the merger agreement with Akorn.

Takeda’s $62bn Shire acquisition is a go following shareholder votes

06-Dec-2018 By Maggie Lynch

Takeda will takeover Shire, after shareholders approved the proposed acquisition, and is expected to close in early 2019.

GSK rebuilds oncology pipeline with $5.1bn acquisition

04-Dec-2018 By Maggie Lynch

GSK entered an agreement with Tesaro to gain ‘under-appreciated’ PARP inhibitor assets and a Boston base.

Unilever to acquire Horlicks and GSK’s Health Food Drinks portfolio

04-Dec-2018 By Rachel Arthur

Unilever will acquire GlaxoSmithKline’s Health Food Drinks portfolio in Asia for €3.3bn ($3.8bn): a move that will boost its presence in the Indian market.

Bayer to shed €600m factor VIII facility and 12,000 staff

30-Nov-2018 By Ben Hargreaves

Bayer looks to boost investor confidence by cutting away its animal health unit, selected consumer health brands and a number of jobs to focus on its life sciences businesses.

Sun Pharma buys Japanese drugmaker with two manufacturing sites

27-Nov-2018 By Flora Southey

Sun Pharma has announced plans to acquire Pola Pharma for $1m, adding topical drug and injectables manufacturing capabilities to its network in Japan.

Cambrex acquires Avista for $252m, becomes integrated CDMO

21-Nov-2018 By Maggie Lynch

Cambrex is set to acquire Avista and enter the market of early stage small molecule development and testing.

European regulators approve Takeda’s acquisition of Shire after divestment

21-Nov-2018 By Maggie Lynch

Takeda’s aim to acquire Shire for $62bn received a boost after regulators vote positively to approve the transaction following the divestment of Shire’s IBD drug.